Can amoxicillin, clarithromycin, and lansoprazole be used together for H. pylori eradication therapy?

Yes, amoxicillin, clarithromycin, and lansoprazole can be used together for H. pylori eradication

This triple therapy combination (lansoprazole + amoxicillin + clarithromycin) is FDA-approved and guideline-recommended as a first-line treatment option for H. pylori infection and duodenal ulcer disease. 1, 2

FDA-Approved Indication

The FDA explicitly approves this combination: amoxicillin in combination with clarithromycin plus lansoprazole as triple therapy is indicated for treating patients with H. pylori infection and duodenal ulcer disease (active or 1-year history) to eradicate H. pylori and reduce duodenal ulcer recurrence risk 1, 2.

Guideline Recommendations with Important Caveats

However, current guidelines (2019) classify this PPI triple therapy (PAC regimen) as "restricted" for first-line use due to rising clarithromycin resistance 3. All three major consensus groups (Toronto, Maastricht V/Florence, and American College of Gastroenterology) agree this regimen should only be used when:

• Local clarithromycin resistance is less than 15%, AND
• The patient has no prior macrolide antibiotic exposure

Dosing and Duration

When this regimen is appropriate, use:

• Lansoprazole 30 mg twice daily
• Amoxicillin 1000 mg twice daily
• Clarithromycin 500 mg twice daily
• Duration: 14 days (all three guidelines recommend 14 days for optimal eradication) 3

Efficacy Data

Eradication rates vary dramatically by region and resistance patterns:

• In optimal conditions with susceptible strains: 94-96% eradication 4, 5
• With clarithromycin-resistant strains: drops to 38-40% 6
• In high-resistance areas: as low as 45.8% 7

The critical factor is clarithromycin susceptibility - resistance reduces treatment success from 98.6% to 76.9% 8.

Preferred First-Line Alternatives

Given increasing resistance, guidelines now favor:

1. Bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline) - particularly in areas with high dual clarithromycin/metronidazole resistance 3

2. Concomitant non-bismuth quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) - when bismuth unavailable 3

Clinical Decision Algorithm

Use lansoprazole + amoxicillin + clarithromycin IF:

• Local clarithromycin resistance <15%, AND
• No prior macrolide exposure, AND
• Bismuth quadruple therapy unavailable or contraindicated

Choose alternative regimen IF:

• Unknown local resistance patterns (assume high resistance)
• Prior macrolide use
• High clarithromycin resistance area (>15%)

Common Pitfall

The major pitfall is using this regimen without considering local antibiotic resistance patterns. What was once a highly effective first-line therapy now fails in over half of patients in many regions due to clarithromycin resistance 7. Do not default to this combination simply because it's familiar or FDA-approved - resistance patterns have fundamentally changed treatment recommendations since the original FDA approval.